Purpureocillium lilacinum is a saprophytic fungus found in soil and decaying organic matter, but has been reported as an emerging pathogen in immunocompromised patients and following surgical procedures. Infections caused by this mold are often difficult to treat because of its intrinsic resistance to conventional antifungal agents and variable susceptibility to novel triazoles. In immunocompetent subjects, infections caused by P. lilacinum are unusual and mainly involve the skin. We describe herein a case of cutaneous hyalohyphomycosis due to this fungus in an immunocompetent girl without any predisposing risk factors and review the previously reported cases in immunocompetent hosts.
Background
Alopecia areata (AA) is an autoimmune condition that usually presents as patchy, nonscarring hair loss. Autoimmune disorders and atopy are reported as comorbid conditions. We aimed to investigate the demographics, clinical characteristics, and associations of AA in Tunisian patients.
Methods
Demographic data, pattern of alopecia, age of onset, and associations were evaluated in 204 patients from January 2012 to June 2016.
Results
Two hundred and four cases of AA were seen. The male to female ratio was 0.68. The mean age at presentation was 23 years old. Positive family history was noticed in 22.1% of patients. Personal history of atopy was associated with AA in 18.1%. Associated autoimmune diseases were thyroid disorders (12.7%), vitiligo (1.5%), psoriasis (three cases), type 1 diabetes (two cases), autoimmune polyendocrinopathy‐candidiasis‐ectodermal dystrophy (APECED) syndrome (two cases), lichen sclerosus atrophicus (one case), and pemphigus vulgaris (one case). Patchy AA was the most common manifestation (49.5%) followed by alopecia universalis (27.5%), alopecia ophiasis (12.7%), and alopecia totalis (10.3%). Nail changes consisting of pitting, trachyonychia, and longitudinal ridging were reported in 24.8%. AA patterns were more severe in females (P = 0.049). Severe forms showed more persistent disease duration (P = 0.005), earlier onset (P = 0.001), and more recurring episodes (P = 0.002) and were significantly associated with nail involvement (P < 0.001).
Conclusions
Our study aimed to review epidemio‐clinical characteristics and comorbid conditions of AA in Tunisian patients. More severe cases with a pejorative value of early‐onset AA, long disease duration, and nail involvement were seen in our study.
Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486 Gawronska-Szklarz B, Luszawska-Kutrzeba T, Czaja-Bulsa G et al. (1999) Relationship between acetylation polymorphism and risk of atopic diseases. Clin Pharmacol Ther 65:562-9 Kardaun SH, Sidoroff A, Valeyrie-Allanore L et al. (2007) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 156:609-11 Kumari R, Timshina DK, Thappa DM (2011) Drug hypersensitivity syndrome. Indian J Dermatol Venereol Leprol 77:7-15 Mallal S, Phillips E, Carosi G et al. (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568-79 Pavlos R, Mallal S, Phillips E (2012) HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 13:1285-306 Shen J, Liu M, Zhou M et al. (2011) Causes of death among active leprosy patients in China. Int J Dermatol 50:57-60 Tian W, Shen J, Zhou M et al. (2012) Dapsone hypersensitivity syndrome among leprosy patients in China. Lepr Rev 83:370-7 Von Schmiedeberg S, Fritsche E, Ronnau AC et al. (1999) Polymorphisms of the xenobioticmetabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv Exp Med Biol 455:147-52
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.